{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T01:14:04Z","timestamp":1791335644431,"version":"4.3.1"},"reference-count":48,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2022,9,17]],"date-time":"2022-09-17T00:00:00Z","timestamp":1663372800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2022,9,17]],"date-time":"2022-09-17T00:00:00Z","timestamp":1663372800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/501100001691","name":"Japan Society for the Promotion of Science","doi-asserted-by":"publisher","award":["16K10696"],"award-info":[{"award-number":["16K10696"]}],"id":[{"id":"10.13039\/501100001691","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001691","name":"Japan Society for the Promotion of Science","doi-asserted-by":"publisher","award":["19K09298"],"award-info":[{"award-number":["19K09298"]}],"id":[{"id":"10.13039\/501100001691","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cancer Immunol Immunother"],"published-print":{"date-parts":[[2023,4]]},"DOI":"10.1007\/s00262-022-03292-4","type":"journal-article","created":{"date-parts":[[2022,9,17]],"date-time":"2022-09-17T17:02:32Z","timestamp":1663434152000},"page":"865-879","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Effects of tumor-infiltrating CD8+ T cells, PD1\/PD-L1 axis, and expression patterns of HLA class I on the prognosis of patients with malignant pleural mesothelioma who underwent extra-pleural pneumonectomy"],"prefix":"10.1007","volume":"72","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1343-1275","authenticated-orcid":false,"given":"Riki","family":"Okita","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuka","family":"Mimura-Kimura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4340-0894","authenticated-orcid":false,"given":"Nobutaka","family":"Kawamoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naoki","family":"Yamamoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masashi","family":"Umeda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masanori","family":"Okada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hidetoshi","family":"Inokawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yusuke","family":"Mimura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomoyuki","family":"Murakami","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masao","family":"Nakata","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazunori","family":"Okabe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,9,17]]},"reference":[{"key":"3292_CR1","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1016\/s0022-5223(99)70469-1","volume":"117","author":"DJ Sugarbaker","year":"1999","unstructured":"Sugarbaker DJ, Flores RM, Jaklitsch MT et al (1999) Resection margins, extrapleural nodal status, and cell type determine postoperative long-term survival in trimodality therapy of malignant pleural mesothelioma: results in 183 patients. J Thorac Cardiovasc Surg 117:54\u201363. https:\/\/doi.org\/10.1016\/s0022-5223(99)70469-1","journal-title":"J Thorac Cardiovasc Surg"},{"key":"3292_CR2","doi-asserted-by":"publisher","first-page":"5485","DOI":"10.1158\/1078-0432.CCR-19-0103","volume":"25","author":"M Okada","year":"2019","unstructured":"Okada M, Kijima T, Aoe K et al (2019) Clinical efficacy and safety of nivolumab: results of a multicenter, open-label, single-arm, Japanese phase II study in malignant pleural mesothelioma (MERIT). Clin Cancer Res 25:5485\u20135492. https:\/\/doi.org\/10.1158\/1078-0432.CCR-19-0103","journal-title":"Clin Cancer Res"},{"key":"3292_CR3","doi-asserted-by":"publisher","first-page":"375","DOI":"10.1016\/S0140-6736(20)32714-8","volume":"397","author":"P Baas","year":"2021","unstructured":"Baas P, Scherpereel A, Nowak AK et al (2021) First-line nivolumab plus ipilimumab in unresectable malignant pleural mesothelioma (CheckMate 743): a multicentre, randomised, open-label, phase 3 trial. Lancet 397:375\u2013386. https:\/\/doi.org\/10.1016\/S0140-6736(20)32714-8","journal-title":"Lancet"},{"key":"3292_CR4","doi-asserted-by":"publisher","first-page":"e221490","DOI":"10.1001\/jamanetworkopen.2022.1490","volume":"5","author":"T Meirson","year":"2022","unstructured":"Meirson T, Pentimalli F, Cerza F et al (2022) Comparison of 3 randomized clinical trials of frontline therapies for malignant pleural mesothelioma. JAMA Netw Open 5:e221490. https:\/\/doi.org\/10.1001\/jamanetworkopen.2022.1490","journal-title":"JAMA Netw Open"},{"key":"3292_CR5","doi-asserted-by":"publisher","first-page":"100280","DOI":"10.1016\/j.jtocrr.2022.100280","volume":"3","author":"K Kerrigan","year":"2022","unstructured":"Kerrigan K, Jo Y, Chipman J, Haaland B, Puri S, Akerley W, Patel S (2022) A real-world analysis of the use of systemic therapy in malignant pleural mesothelioma and the differential impacts on overall survival by practice pattern. JTO Clin Res Rep 3:100280. https:\/\/doi.org\/10.1016\/j.jtocrr.2022.100280","journal-title":"JTO Clin Res Rep"},{"key":"3292_CR6","doi-asserted-by":"publisher","first-page":"1643","DOI":"10.1126\/science.1840703","volume":"254","author":"P van der Bruggen","year":"1991","unstructured":"van der Bruggen P, Traversari C, Chomez P, Lurquin C, De Plaen E, Van den Eynde B, Knuth A, Boon T (1991) A gene encoding an antigen recognized by cytolytic T lymphocytes on a human melanoma. Science 254:1643\u20131647. https:\/\/doi.org\/10.1126\/science.1840703","journal-title":"Science"},{"key":"3292_CR7","doi-asserted-by":"publisher","first-page":"491","DOI":"10.1016\/0167-5699(93)90264-L","volume":"14","author":"F Garrido","year":"1993","unstructured":"Garrido F, Cabrera T, Concha A, Glew S, Ruiz-Cabello F, Stern PL (1993) Natural history of HLA expression during tumour development. Immunol Today 14:491\u2013499. https:\/\/doi.org\/10.1016\/0167-5699(93)90264-L","journal-title":"Immunol Today"},{"key":"3292_CR8","first-page":"1275","volume":"24","author":"B Seliger","year":"1996","unstructured":"Seliger B, Harders C, Wollscheid U, Staege MS, Reske-Kunz AB, Huber C (1996) Suppression of MHC class I antigens in oncogenic transformants: association with decreased recognition by cytotoxic T lymphocytes. Exp Hematol 24:1275\u20131279","journal-title":"Exp Hematol"},{"key":"3292_CR9","doi-asserted-by":"publisher","first-page":"646","DOI":"10.1016\/j.cell.2011.02.013","volume":"144","author":"D Hanahan","year":"2011","unstructured":"Hanahan D, Weinberg RA (2011) Hallmarks of cancer: the next generation. Cell 144:646\u2013674. https:\/\/doi.org\/10.1016\/j.cell.2011.02.013","journal-title":"Cell"},{"key":"3292_CR10","doi-asserted-by":"publisher","first-page":"1027","DOI":"10.1084\/jem.192.7.1027","volume":"192","author":"GJ Freeman","year":"2000","unstructured":"Freeman GJ, Long AJ, Iwai Y et al (2000) Engagement of the PD-1 immunoinhibitory receptor by a novel B7 family member leads to negative regulation of lymphocyte activation. J Exp Med 192:1027\u20131034. https:\/\/doi.org\/10.1084\/jem.192.7.1027","journal-title":"J Exp Med"},{"key":"3292_CR11","doi-asserted-by":"publisher","first-page":"18538","DOI":"10.1073\/pnas.0509182102","volume":"102","author":"E Sato","year":"2005","unstructured":"Sato E, Olson SH, Ahn J et al (2005) Intraepithelial CD8+ tumor-infiltrating lymphocytes and a high CD8+\/regulatory T cell ratio are associated with favorable prognosis in ovarian cancer. Proc Natl Acad Sci USA 102:18538\u201318543. https:\/\/doi.org\/10.1073\/pnas.0509182102","journal-title":"Proc Natl Acad Sci USA"},{"key":"3292_CR12","doi-asserted-by":"publisher","first-page":"13765","DOI":"10.18632\/oncotarget.7282","volume":"7","author":"DQ Zeng","year":"2016","unstructured":"Zeng DQ, Yu YF, Ou QY, Li XY, Zhong RZ, Xie CM, Hu QG (2016) Prognostic and predictive value of tumor-infiltrating lymphocytes for clinical therapeutic research in patients with non-small cell lung cancer. Oncotarget 7:13765\u201313781. https:\/\/doi.org\/10.18632\/oncotarget.7282","journal-title":"Oncotarget"},{"key":"3292_CR13","doi-asserted-by":"publisher","first-page":"1543","DOI":"10.1007\/s00262-010-0881-6","volume":"59","author":"N Yamada","year":"2010","unstructured":"Yamada N, Oizumi S, Kikuchi E et al (2010) CD8+ tumor-infiltrating lymphocytes predict favorable prognosis in malignant pleural mesothelioma after resection. Cancer Immunol Immunother 59:1543\u20131549. https:\/\/doi.org\/10.1007\/s00262-010-0881-6","journal-title":"Cancer Immunol Immunother"},{"key":"3292_CR14","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1002\/path.5361","volume":"250","author":"S Inaguma","year":"2020","unstructured":"Inaguma S, Lasota J, Czapiewski P et al (2020) CD70 expression correlates with a worse prognosis in malignant pleural mesothelioma patients via immune evasion and enhanced invasiveness. J Pathol 250:205\u2013216. https:\/\/doi.org\/10.1002\/path.5361","journal-title":"J Pathol"},{"key":"3292_CR15","doi-asserted-by":"publisher","first-page":"566","DOI":"10.1002\/ijc.1362","volume":"93","author":"A Zia","year":"2001","unstructured":"Zia A, Schildberg FW, Funke I (2001) MHC class I negative phenotype of disseminated tumor cells in bone marrow is associated with poor survival in R0M0 breast cancer patients. Int J Cancer 93:566\u2013570. https:\/\/doi.org\/10.1002\/ijc.1362","journal-title":"Int J Cancer"},{"key":"3292_CR16","doi-asserted-by":"publisher","first-page":"1424","DOI":"10.1111\/j.1349-7006.2007.00558.x","volume":"98","author":"E Kikuchi","year":"2007","unstructured":"Kikuchi E, Yamazaki K, Torigoe T, Cho Y, Miyamoto M, Oizumi S, Hommura F, Dosaka-Akita H, Nishimura M (2007) HLA class I antigen expression is associated with a favorable prognosis in early stage non-small cell lung cancer. Cancer Sci 98:1424\u20131430. https:\/\/doi.org\/10.1111\/j.1349-7006.2007.00558.x","journal-title":"Cancer Sci"},{"key":"3292_CR17","doi-asserted-by":"publisher","first-page":"865","DOI":"10.1007\/s00262-017-1986-y","volume":"66","author":"R Okita","year":"2017","unstructured":"Okita R, Maeda A, Shimizu K, Nojima Y, Saisho S, Nakata M (2017) PD-L1 overexpression is partially regulated by EGFR\/HER2 signaling and associated with poor prognosis in patients with non-small-cell lung cancer. Cancer Immunol Immunother 66:865\u2013876. https:\/\/doi.org\/10.1007\/s00262-017-1986-y","journal-title":"Cancer Immunol Immunother"},{"key":"3292_CR18","doi-asserted-by":"publisher","first-page":"1361","DOI":"10.1016\/j.ejca.2014.01.018","volume":"50","author":"CY Yang","year":"2014","unstructured":"Yang CY, Lin MW, Chang YL, Wu CT, Yang PC (2014) Programmed cell death-ligand 1 expression in surgically resected stage I pulmonary adenocarcinoma and its correlation with driver mutations and clinical outcomes. Eur J Cancer 50:1361\u20131369. https:\/\/doi.org\/10.1016\/j.ejca.2014.01.018","journal-title":"Eur J Cancer"},{"key":"3292_CR19","doi-asserted-by":"publisher","first-page":"e0121071","DOI":"10.1371\/journal.pone.0121071","volume":"10","author":"S Cedr\u00e9s","year":"2015","unstructured":"Cedr\u00e9s S, Ponce-Aix S, Zugazagoitia J, Sansano I, Enguita A, Navarro-Mendivil A, Martinez-Marti A, Martinez P, Felip E (2015) Analysis of expression of programmed cell death 1 ligand 1 (PD-L1) in malignant pleural mesothelioma (MPM). PLoS ONE 10:e0121071. https:\/\/doi.org\/10.1371\/journal.pone.0121071","journal-title":"PLoS ONE"},{"key":"3292_CR20","doi-asserted-by":"publisher","first-page":"850","DOI":"10.1016\/j.jtho.2017.02.013","volume":"12","author":"B Thapa","year":"2017","unstructured":"Thapa B, Salcedo A, Lin X et al (2017) The immune microenvironment, genome-wide copy number aberrations, and survival in mesothelioma. J Thorac Oncol 12:850\u2013859. https:\/\/doi.org\/10.1016\/j.jtho.2017.02.013","journal-title":"J Thorac Oncol"},{"key":"3292_CR21","doi-asserted-by":"publisher","first-page":"20769","DOI":"10.18632\/oncotarget.25100","volume":"9","author":"T Watanabe","year":"2018","unstructured":"Watanabe T, Okuda K, Murase T et al (2018) Four immunohistochemical assays to measure the PD-L1 expression in malignant pleural mesothelioma. Oncotarget 9:20769\u201320780. https:\/\/doi.org\/10.18632\/oncotarget.25100","journal-title":"Oncotarget"},{"key":"3292_CR22","doi-asserted-by":"publisher","first-page":"2082","DOI":"10.1016\/j.jtcvs.2019.10.122","volume":"159","author":"M de Perrot","year":"2020","unstructured":"de Perrot M, Wu L, Cabanero M et al (2020) Prognostic influence of tumor microenvironment after hypofractionated radiation and surgery for mesothelioma. J Thorac Cardiovasc Surg 159:2082-2091.e1. https:\/\/doi.org\/10.1016\/j.jtcvs.2019.10.122","journal-title":"J Thorac Cardiovasc Surg"},{"key":"3292_CR23","doi-asserted-by":"publisher","first-page":"1627","DOI":"10.1056\/NEJMoa1507643","volume":"373","author":"H Borghaei","year":"2015","unstructured":"Borghaei H, Paz-Ares L, Horn L et al (2015) Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer. N Engl J Med 373:1627\u20131639. https:\/\/doi.org\/10.1056\/NEJMoa1507643","journal-title":"N Engl J Med"},{"key":"3292_CR24","doi-asserted-by":"publisher","first-page":"508","DOI":"10.1245\/s10434-016-5376-z","volume":"23","author":"S Ito","year":"2016","unstructured":"Ito S, Okano S, Morita M et al (2016) Expression of PD-L1 and HLA class I in esophageal squamous cell carcinoma: prognostic factors for patient outcome. Ann Surg Oncol 23:508\u2013515. https:\/\/doi.org\/10.1245\/s10434-016-5376-z","journal-title":"Ann Surg Oncol"},{"key":"3292_CR25","doi-asserted-by":"publisher","first-page":"771","DOI":"10.1007\/s00262-020-02506-x","volume":"69","author":"DP Hurkmans","year":"2020","unstructured":"Hurkmans DP, Kuipers ME, Smit J, van Marion R, Mathijssen RHJ, Postmus PE, Hiemstra PS, Aerts JGJV, von der Th\u00fcsen JH, van der Burg SH (2020) Tumor mutational load, CD8+ T cells, expression of PD-L1 and HLA class I to guide immunotherapy decisions in NSCLC patients. Cancer Immunol Immunother 69:771\u2013777. https:\/\/doi.org\/10.1007\/s00262-020-02506-x","journal-title":"Cancer Immunol Immunother"},{"key":"3292_CR26","volume-title":"WHO Classification of Tumours of the Lung, Pleura, Thymus and Heart","author":"WD Travis","year":"2015","unstructured":"Travis WD, International Agency for Research on C (2015) WHO Classification of Tumours of the Lung, Pleura, Thymus and Heart. International Agency for Research on Cancer"},{"key":"3292_CR27","doi-asserted-by":"publisher","first-page":"2089","DOI":"10.1016\/j.jtho.2016.08.147","volume":"11","author":"AK Nowak","year":"2016","unstructured":"Nowak AK, Chansky K, Rice DC et al (2016) The IASLC Mesothelioma Staging Project: proposals for revisions of the T descriptors in the forthcoming eighth edition of the TNM classification for pleural mesothelioma. J Thorac Oncol 11:2089\u20132099. https:\/\/doi.org\/10.1016\/j.jtho.2016.08.147","journal-title":"J Thorac Oncol"},{"key":"3292_CR28","doi-asserted-by":"publisher","first-page":"2100","DOI":"10.1016\/j.jtho.2016.09.121","volume":"11","author":"D Rice","year":"2016","unstructured":"Rice D, Chansky K, Nowak A et al (2016) The IASLC Mesothelioma Staging Project: proposals for revisions of the N descriptors in the forthcoming eighth edition of the TNM classification for pleural mesothelioma. J Thorac Oncol 11:2100\u20132111. https:\/\/doi.org\/10.1016\/j.jtho.2016.09.121","journal-title":"J Thorac Oncol"},{"key":"3292_CR29","doi-asserted-by":"publisher","first-page":"2112","DOI":"10.1016\/j.jtho.2016.09.124","volume":"11","author":"VW Rusch","year":"2016","unstructured":"Rusch VW, Chansky K, Kindler HL et al (2016) The IASLC Mesothelioma Staging Project: proposals for the M descriptors and for revision of the TNM Stage groupings in the forthcoming (Eighth) edition of the TNM classification for mesothelioma. J Thorac Oncol 11:2112\u20132119. https:\/\/doi.org\/10.1016\/j.jtho.2016.09.124","journal-title":"J Thorac Oncol"},{"key":"3292_CR30","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1510\/icvts.2007.16632","volume":"7","author":"M Okada","year":"2008","unstructured":"Okada M, Mimura T, Ohbayashi C, Sakuma T, Soejima T, Tsubota N (2008) Radical surgery for malignant pleural mesothelioma: results and prognosis. Interact Cardiovasc Thorac Surg 7:102\u2013106. https:\/\/doi.org\/10.1510\/icvts.2007.16632","journal-title":"Interact Cardiovasc Thorac Surg"},{"key":"3292_CR31","doi-asserted-by":"publisher","first-page":"1799","DOI":"10.1016\/s0003-4975(99)01038-3","volume":"68","author":"VW Rusch","year":"1999","unstructured":"Rusch VW, Venkatraman ES (1999) Important prognostic factors in patients with malignant pleural mesothelioma, managed surgically. Ann Thorac Surg 68:1799\u20131804. https:\/\/doi.org\/10.1016\/s0003-4975(99)01038-3","journal-title":"Ann Thorac Surg"},{"key":"3292_CR32","doi-asserted-by":"publisher","first-page":"248","DOI":"10.1002\/ijc.21163","volume":"117","author":"Z Madjd","year":"2005","unstructured":"Madjd Z, Spendlove I, Pinder SE, Ellis IO, Durrant LG (2005) Total loss of MHC class I is an independent indicator of good prognosis in breast cancer. Int J Cancer 117:248\u2013255. https:\/\/doi.org\/10.1002\/ijc.21163","journal-title":"Int J Cancer"},{"key":"3292_CR33","doi-asserted-by":"publisher","first-page":"e77025","DOI":"10.1371\/journal.pone.0077025","volume":"8","author":"A N\u00e4sman","year":"2013","unstructured":"N\u00e4sman A, Andersson E, Marklund L et al (2013) HLA class I and II expression in oropharyngeal squamous cell carcinoma in relation to tumor HPV status and clinical outcome. PLoS ONE 8:e77025. https:\/\/doi.org\/10.1371\/journal.pone.0077025","journal-title":"PLoS ONE"},{"key":"3292_CR34","doi-asserted-by":"publisher","first-page":"740","DOI":"10.1002\/(sici)1097-0215(19981209)78:6<740::aid-ijc12>3.0.co;2-5","volume":"78","author":"L Mutti","year":"1998","unstructured":"Mutti L, Valle MT, Balbi B, Orengo AM, Lazzaro A, Alciato P, Gatti E, Betta PG, Pozzi E (1998) Primary human mesothelioma cells express class II MHC, ICAM-1 and B7\u20132 and can present recall antigens to autologous blood lymphocytes. Int J Cancer 78:740\u2013749. https:\/\/doi.org\/10.1002\/(sici)1097-0215(19981209)78:6%3c740::aid-ijc12%3e3.0.co;2-5","journal-title":"Int J Cancer"},{"key":"3292_CR35","doi-asserted-by":"publisher","first-page":"260","DOI":"10.1136\/oem.17.4.260","volume":"17","author":"JC Wagner","year":"1960","unstructured":"Wagner JC, Sleggs CA, Marchand P (1960) Diffuse pleural mesothelioma and asbestos exposure in the North Western Cape Province. Br J Ind Med 17:260\u2013271. https:\/\/doi.org\/10.1136\/oem.17.4.260","journal-title":"Br J Ind Med"},{"key":"3292_CR36","doi-asserted-by":"publisher","first-page":"3948","DOI":"10.4049\/jimmunol.174.7.3948","volume":"174","author":"MC Rouyez","year":"2005","unstructured":"Rouyez MC, Lestingi M, Charon M, Fichelson S, Buzyn A, Dusanter-Fourt I (2005) IFN regulatory factor-2 cooperates with STAT1 to regulate transporter associated with antigen processing-1 promoter activity. J Immunol 174:3948\u20133958. https:\/\/doi.org\/10.4049\/jimmunol.174.7.3948","journal-title":"J Immunol"},{"key":"3292_CR37","doi-asserted-by":"publisher","first-page":"775","DOI":"10.1111\/1759-7714.13847","volume":"12","author":"R Okita","year":"2021","unstructured":"Okita R, Shimizu K, Nojima Y, Saisho S, Nakata M (2021) Tofacitinib overcomes an IFN\u03b3-induced decrease in NK cell-mediated cytotoxicity via the regulation of immune-related molecules in LC-2\/ad. Thorac Cancer 12:775\u2013782. https:\/\/doi.org\/10.1111\/1759-7714.13847","journal-title":"Thorac Cancer"},{"key":"3292_CR38","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1093\/carcin\/bgv174","volume":"37","author":"RA Pietrofesa","year":"2016","unstructured":"Pietrofesa RA, Velalopoulou A, Arguiri E, Menges CW, Testa JR, Hwang WT, Albelda SM, Christofidou-Solomidou M (2016) Flaxseed lignans enriched in secoisolariciresinol diglucoside prevent acute asbestos-induced peritoneal inflammation in mice. Carcinogenesis 37:177\u2013187. https:\/\/doi.org\/10.1093\/carcin\/bgv174","journal-title":"Carcinogenesis"},{"key":"3292_CR39","doi-asserted-by":"publisher","first-page":"1366","DOI":"10.1038\/s12276-021-00670-3","volume":"53","author":"F Du","year":"2021","unstructured":"Du F, Qi X, Zhang A, Sui F, Wang X, Proud CG, Lin C, Fan X, Li J (2021) MRTF-A-NF-\u03baB\/p65 axis-mediated PDL1 transcription and expression contributes to immune evasion of non-small-cell lung cancer via TGF-\u03b2. Exp Mol Med 53:1366\u20131378. https:\/\/doi.org\/10.1038\/s12276-021-00670-3","journal-title":"Exp Mol Med"},{"key":"3292_CR40","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1016\/j.molimm.2014.12.017","volume":"65","author":"XH Chen","year":"2015","unstructured":"Chen XH, Liu ZC, Zhang G et al (2015) TGF-\u03b2 and EGF induced HLA-I downregulation is associated with epithelial-mesenchymal transition (EMT) through upregulation of snail in prostate cancer cells. Mol Immunol 65:34\u201342. https:\/\/doi.org\/10.1016\/j.molimm.2014.12.017","journal-title":"Mol Immunol"},{"key":"3292_CR41","first-page":"161","volume":"11","author":"MT Valle","year":"2003","unstructured":"Valle MT, Porta C, Megiovanni AM, Libener R, Mele L, Gaudino G, Strizzi L, Guida R, Toma S, Mutti L (2003) Transforming growth factor-beta released by PPD-presenting malignant mesothelioma cells inhibits interferon-gamma synthesis by an anti-PPD CD4+ T-cell clone. Int J Mol Med 11:161\u2013167","journal-title":"Int J Mol Med"},{"key":"3292_CR42","doi-asserted-by":"publisher","first-page":"342","DOI":"10.4161\/cbt.4.3.1644","volume":"4","author":"P DeLong","year":"2005","unstructured":"DeLong P, Carroll RG, Henry AC, Tanaka T, Ahmad S, Leibowitz MS, Sterman DH, June CH, Albelda SM, Vonderheide RH (2005) Regulatory T cells and cytokines in malignant pleural effusions secondary to mesothelioma and carcinoma. Cancer Biol Ther 4:342\u2013346. https:\/\/doi.org\/10.4161\/cbt.4.3.1644","journal-title":"Cancer Biol Ther"},{"key":"3292_CR43","doi-asserted-by":"publisher","first-page":"2442","DOI":"10.1158\/1078-0432.CCR-18-2652","volume":"25","author":"PF Wong","year":"2019","unstructured":"Wong PF, Wei W, Smithy JW, Acs B, Toki MI, Blenman KRM, Zelterman D, Kluger HM, Rimm DL (2019) Multiplex quantitative analysis of tumor-infiltrating lymphocytes and immunotherapy outcome in metastatic melanoma. Clin Cancer Res 25:2442\u20132449. https:\/\/doi.org\/10.1158\/1078-0432.CCR-18-2652","journal-title":"Clin Cancer Res"},{"key":"3292_CR44","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1016\/j.canlet.2021.06.008","volume":"517","author":"H Wang","year":"2021","unstructured":"Wang H, Liu B, Wei J (2021) Beta2-microglobulin (B2M) in cancer immunotherapies: biological function, resistance and remedy. Cancer Lett 517:96\u2013104. https:\/\/doi.org\/10.1016\/j.canlet.2021.06.008","journal-title":"Cancer Lett"},{"key":"3292_CR45","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1038\/nri2073","volume":"7","author":"HG Ljunggren","year":"2007","unstructured":"Ljunggren HG, Malmberg KJ (2007) Prospects for the use of NK cells in immunotherapy of human cancer. Nat Rev Immunol 7:329\u2013339. https:\/\/doi.org\/10.1038\/nri2073","journal-title":"Nat Rev Immunol"},{"key":"3292_CR46","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.immuni.2013.07.012","volume":"39","author":"DS Chen","year":"2013","unstructured":"Chen DS, Mellman I (2013) Oncology meets immunology: the cancer-immunity cycle. Immunity 39:1\u201310. https:\/\/doi.org\/10.1016\/j.immuni.2013.07.012","journal-title":"Immunity"},{"key":"3292_CR47","doi-asserted-by":"publisher","first-page":"763","DOI":"10.1016\/S1470-2045(11)70149-8","volume":"12","author":"T Treasure","year":"2011","unstructured":"Treasure T, Lang-Lazdunski L, Waller D et al (2011) Extra-pleural pneumonectomy versus no extra-pleural pneumonectomy for patients with malignant pleural mesothelioma: clinical outcomes of the Mesothelioma and Radical Surgery (MARS) randomised feasibility study. Lancet Oncol 12:763\u2013772. https:\/\/doi.org\/10.1016\/S1470-2045(11)70149-8","journal-title":"Lancet Oncol"},{"key":"3292_CR48","doi-asserted-by":"publisher","first-page":"1348","DOI":"10.1016\/j.athoracsur.2021.04.04","volume":"113","author":"M Hashimoto","year":"2022","unstructured":"Hashimoto M, Yamamoto H, Endo S, Okada M, Miyata H, Hasegawa S, Chida M (2022) Japanese current status of curative-intent surgery for malignant pleural mesothelioma. Ann Thorac Surg 113:1348\u20131353. https:\/\/doi.org\/10.1016\/j.athoracsur.2021.04.04","journal-title":"Ann Thorac Surg"}],"container-title":["Cancer Immunology, Immunotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00262-022-03292-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00262-022-03292-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00262-022-03292-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,3,27]],"date-time":"2023-03-27T01:48:35Z","timestamp":1679881715000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00262-022-03292-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,9,17]]},"references-count":48,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2023,4]]}},"alternative-id":["3292"],"URL":"https:\/\/doi.org\/10.1007\/s00262-022-03292-4","relation":{},"ISSN":["0340-7004","1432-0851"],"issn-type":[{"value":"0340-7004","type":"print"},{"value":"1432-0851","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,9,17]]},"assertion":[{"value":"31 January 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 September 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 September 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Dr. Masao Nakata received research funding from Nihon Medi-Physics Co., Ltd., Taiho Pharmaceutical Co., Ltd., Chugai Pharmaceutical Co., Ltd., and Eli Lilly Japan K.K. for research outside the scope of the submitted work. All other authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interests"}},{"value":"This research was approved by the Yamaguchi Ube Medical Center ethics committee (No. 30-5); it followed the principles of the Declaration of Helsinki and was in compliance with the relevant guidelines and regulations.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Written informed consent for the use of tissue samples and medical records was waived, and an opt-out method on the website was applied to obtain patient consent; however, written informed consent was obtained from all living patients or patients treated at our hospital after October 2012.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}}]}}